Sections
Shows
Drugs Controller General Of India
Recent Highlights
All Stories for Drugs Controller General Of India
DCGI approves DRDO's drug that helps reduce oxygen dependency in COVID-19 patients
•The drug 2-deoxy-D-glucose (2-DG) comes in powder form in a sachet and is taken orally by dissolving it in water, the defence ministry said
WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months
•The UN body has also sought a meeting with the Drugs Controller General of India to discuss the matter 10:12
Pfizer withdraws application for emergency use authorisation of its COVID-19 vaccine in India
•In a statement, Pfizer said it had decided to withdraw the application after a meeting with the Drug Regulatory Authority of India on 3 Feb, in which the regulator stated that there may be need for "additional information"
COVID-19 panel recommends SII's Covishield for emergency use; new cases remain under 30,000 for 19th day
Fp Staff •The daily new coronavirus infections in India remained below 30,000 for the 19th consecutive day on Friday, taking the total caseload to 1,02,86,709
Indian regulator seeks more time as UK authorises Oxford COVID-19 jab; six things about cheap, easy to store vaccine
Fp Staff •In India, a decision on emergency usage of the vaccine, which is being manufactured by Pune-based Serum Institute of India, is likely to come next year with the Subject Expert Committee (SEC) on COVID-19 seeking more time today
CDSCO asks Bharat Biotech to submit complete immunogenicity data of Phase 2 trial of COVID-19 vaccine
•The vaccine candidate, 'Covaxin', is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research
DCGI approves commercial launch of Tata Group's low-cost COVID-19 test 'Feluda'
•This test uses an indigenously-developed, cutting-edge CRISPR technology for detecting the virus' genome sequence
Serum Institute of India gets DCGI's nod to resume clinical trial of Oxford COVID-19 vaccine
•SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events
India readies five sites for final phase of human trials of Oxford's COVID-19 vaccine
•Serum Institute of India has been chosen by Oxford University and its partner AstraZeneca to manufacture the COVID-19 vaccine
DCGI approves psoriasis injection for 'restricted emergency use' to treat COVID-19 patients
•Drugs Controller General of India approved monoclonal antibody injection Itolizumab for limited use to treat moderate to severe cases of COVID-19.